TECVAYLI®▼ (Teclistamab) Demonstrates Potential As Frontline Combination Therapy For Patients With Newly Diagnosed Multiple Myeloma
TECVAYLI®▼ (Teclistamab) Demonstrates Potential As Frontline Combination Therapy For Patients With Newly Diagnosed Multiple Myeloma . (MENAFN - GlobeNewsWire - Nasdaq) 100 percent of evaluable patients for minimal residual disease (MRD) testing achieved MRD negativity in MajesTEC-5 as induction therapy and MajesTEC-4 as ...
América - MenaFN
Jordania
https://menafn.com/images/Menafn_SmallLogo.jpg
https://menafn.com/1108968683/TECVAYLI-Teclistamab-Demonstrates-Potential-As-Frontline-Combination-Therapy-For-Patients-With-Newly-Diagnosed-Multiple-Myeloma
2024-12-08
rss
(MENAFN - GlobeNewsWire - Nasdaq) 100 percent of evaluable patients for minimal residual disease (MRD) testing achieved MRD negativity in MajesTEC-5 as induction therapy and MajesTEC-4 as ...
TECVAYLI®▼ (Teclistamab) Demonstrates Potential As Frontline Combination Therapy For Patients With Newly Diagnosed Multiple Myeloma